Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Calgary

$39,000.00

The gal-lectin in host defence against entamoeba histolytica

FY 2011-12

Summary
Entamoeba histolytica is a parasitic protozoan that causes the disease amebiasis characterized by bloody dysentery and liver abscess. About 1% of the world's population carries the parasite, resulting in 50 million cases of invasive disease and 100,000 deaths per year. It is among the 10 leading causes of mortality worldwide. At present, it is not known why the parasites are not controlled during infection. However, patients who are drug-cured are resistant to reinvasion suggesting that protective immunity occurs. Clinical and experimental studies indicate that cell-mediated immunity mediated by macrophages (the white blood cells that kill the parasites) is important in control and resistance to re-infection. Thus, a priority to the control of amebiasis is to develop a safe and effective vaccine. The major surface molecule on the parasite involved in the initiation of disease is the galactose-binding protein called the Gal-lectin. This protein is immunodominant and is recognized by serum from patients who had/has the disease. Immunization of animals with the Gal-lectin protected them against a challenge infection suggesting it is a good vaccine candidate molecule against amebiasis. However, it is not known what portion(s) of the Gal-lectin elicits the protective immune response. We hypothesized that specific portions of the Gal-lectin stimulates cell-mediated immunity for host defense against the disease. Accordingly, the specific aims of this study are: (1) to identify the critical regions of the Gal-lectin that stimulate innate and adaptive immune responses and, (2) to identify the host cell receptor and the signaling events involved in protective immunity. Our strategy is to first fine map the protective epitopes of the Gal-lectin using a panel of monoclonal antibodies that recognize distinct domains. Secondly, we will identify the receptors on dendritic cells that stimulate a protective immune response by using cells and animals that are deficient in the putative receptor(s) for the Gal-lectin. Characterizing the receptor and the signaling events involved in stimulating the right immune response is important in developing strategies to enhance vaccine development against this devastating disease.
Program
Discovery Grants Program - Individual
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
121785-2008
Name nom
Chadee, Khrisendath
Department département
Microbiology and Infectious Diseases
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2011
Competition year année de concours
2008
Award amount
39000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
32
Committee name en
Cell Biology
Committee name fr
Biologie cellulaire
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Immunology
Research subject fr
Immunologie
Partie
4
Nb partie
5
Application title
The gal-lectin in host defence against entamoeba histolytica
Keyword
NSERC
Application summary
Entamoeba histolytica is a parasitic protozoan that causes the disease amebiasis characterized by bloody dysentery and liver abscess. About 1% of the world's population carries the parasite, resulting in 50 million cases of invasive disease and 100,000 deaths per year. It is among the 10 leading causes of mortality worldwide. At present, it is not known why the parasites are not controlled during infection. However, patients who are drug-cured are resistant to reinvasion suggesting that protective immunity occurs. Clinical and experimental studies indicate that cell-mediated immunity mediated by macrophages (the white blood cells that kill the parasites) is important in control and resistance to re-infection. Thus, a priority to the control of amebiasis is to develop a safe and effective vaccine. The major surface molecule on the parasite involved in the initiation of disease is the galactose-binding protein called the Gal-lectin. This protein is immunodominant and is recognized by serum from patients who had/has the disease. Immunization of animals with the Gal-lectin protected them against a challenge infection suggesting it is a good vaccine candidate molecule against amebiasis. However, it is not known what portion(s) of the Gal-lectin elicits the protective immune response. We hypothesized that specific portions of the Gal-lectin stimulates cell-mediated immunity for host defense against the disease. Accordingly, the specific aims of this study are: (1) to identify the critical regions of the Gal-lectin that stimulate innate and adaptive immune responses and, (2) to identify the host cell receptor and the signaling events involved in protective immunity. Our strategy is to first fine map the protective epitopes of the Gal-lectin using a panel of monoclonal antibodies that recognize distinct domains. Secondly, we will identify the receptors on dendritic cells that stimulate a protective immune response by using cells and animals that are deficient in the putative receptor(s) for the Gal-lectin. Characterizing the receptor and the signaling events involved in stimulating the right immune response is important in developing strategies to enhance vaccine development against this devastating disease.